Reprogramming progenitor compositions and methods of use therefore

Patent metadata

Field	Value
Publication number	US-10920199-B2
Application number	US-201615552476-A
Country	US
Kind code	B2
Filing date	Feb 26, 2016
Priority date	Feb 27, 2015
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.

First claim

What is claimed is:

1. A method of obtaining a reprogrammed murine induced pluripotent stem cell, the method comprising: (a) transducing mouse embryonic fibroblast progenitor cells with one or more viral vectors comprising polynucleotides encoding expressing Oct4, Sox2, Klf4 and cMyc reprogramming factors; (b) inducing in the cells a transient oxidative burst comprising an at least 2-fold increase in oxidative phosphorylation and metabolicactivity and an increased level of at least one analyte selected from nicotinamide adenine dinucleotide (NADH), a ketoglutarate, cellular ATP, ATP synthase in mitochondria (ATP5G1), succinate dehydrogenase (SDHB), isocitrate dehydrogenase (IDH3), NADH dehydrogenase (NDUFA2), superoxide dismutase 2 (SOD2), NADPH oxidase 4 (NOX4), or catalase (CAT) by transducing the mouse embryonic fibroblast progenitor cells with a viral vector comprising a polynucleotide encoding estrogen related receptor gamma (ERRγ) and expressing ERRγ in the cells 3-5 days following step (a), wherein the expression of ERRγ in the cells results in the upregulation of at least one ERRγ cofactor selected from Peroxisome proliferator-activated receptor Gamma Coactivator 1 alpha (PGC-1α) or Peroxisome proliferator-activated receptor Gamma Coactivator 1 beta (PGC-1β) in the cells, thereby facilitating reprogramming and inducing pluripotency in the cells; (c) obtaining a reprogrammed murine induced pluripotent stem cell; and, (d) optionally, isolating said reprogrammed murine induced pluripotent stem cell from the culture.

2. A method of obtaining a reprogrammed human induced pluripotent stem cell, the method comprising: (a) transducing human fibroblast progenitor cells or human adipose stem cell progenitor cells with one or more viral vectors comprising polynucleotides encoding Oct4, Sox2, Klf4 and cMyc reprogramming factors; (b) inducing in the cells a transient oxidative burst comprising an at least 2-fold increase in oxidative phosphorylation and metabolicactivity and an increased level of at least one analyte selected from nicotinamide adenine dinucleotide (NADH), a-ketoglutarate, cellular ATP, ATP synthase in mitochondria (ATP5G1), succinate dehydrogenase (SDHB), isocitrate dehydrogenase (IDH3), NADH dehydrogenase (NDUFA2), superoxide dismutase 2 (SOD2), NADPH oxidase 4 (NOX4), or catalase (CAT) by transducing the human fibroblast progenitor cells or the human adipose stem cell progenitor cells with a viral vector comprising a polynucleotide encoding estrogen related receptor alpha (ERRα) and expressing ERRα in the cells 3-5 days following step (a), wherein the expression of ERRα in the cells results in the upregulation of at least one ERRα cofactor selected from Peroxisome proliferator activated receptor Gamma Coactivator 1 alpha (PGC-1α) or Peroxisome proliferator-activated receptor Gamma Coactivator 1 beta (PGC-113), in the cells, thereby facilitating reprogramming and inducing pluripotency in the cells; (c) obtaining a reprogrammed human induced pluripotent stem cell; and, (d) optionally, isolating said reprogrammed human induced pluripotent stem cell from the culture.

3. A method of generating a reprogrammed human induced pluripotent stem cell, the method comprising:
(a) transducing human fibroblast progenitor cells or human adipose stem cell progenitor cells with one or more viral vectors comprising polynucleotides encoding recombinant Oct4, Sox2, Klf4 and cMyc reprogramming factors;
(b) inducing in the cell a transient oxidative burst comprising an at least 2-fold increase in oxidative phosphorylation and metabolic activity and an increased level of at least one analyte selected from nicotinamide adenine dinucleotide (NADH), a-ketoglutarate, cellular ATP, ATP synthase in mitochondria (ATP5G1), succinate dehydrogenase (SDHB), isocitrate dehydrogenase (IDH3), NADH dehydrogenase (NDUFA2), superoxide dismutase 2 (SOD2), NADPH oxidase 4 (NOX4), or catalase (CAT) by transducing the human fibroblast progenitor cells or the human adipose stem cell progenitor cells with a viral vector comprising a polynucleotide encoding estrogen related receptor alpha (ERRa) and expressing ERRα in the cells 3-5 days following step (a), wherein the expression of ERRα in the cells results in the upregulation of at least one ERRα cofactor selected from Peroxisome proliferator-activated receptor Gamma Coactivator 1 alpha PGC-1α) or Peroxisome proliferator-activated receptor Gamma Coactivator 1 beta (PGC-1β) in the cells; and
(c) culturing the human cells, thereby generating a reprogrammed human induced pluripotent stem cell.

4. A method of generating a reprogrammed mammalian induced pluripotent stem cell, the method comprising:
(a) transducing mammalian fibroblast progenitor cells or mammalian adipose stem cell progenitor cells with one or more viral vectors comprising polynucleotides encoding Oct4, Sox2, Klf4 and cMyc-reprogramming factors;
(b) inducing in the cells a transient oxidative burst comprising an at least 2-fold increase in oxidative phosphorylation and metabolic activity and increased levels of at least one analyte selected from nicotinamide adenine dinucleotide (NADH), a-ketoglutarate, cellular ATP, ATP synthase in mitochondria (ATP5G1), succinate dehydrogenase (SDHB), isocitrate dehydrogenase (IDH3), NADH dehydrogenase (NDUFA2), superoxide dismutase 2 (SOD2), NADPH oxidase 4 (NOX4), or catalase (CAT) by transducing the mammalian fibroblast progenitor cells or mammalian adipose stem cell progenitor cells with a viral vector comprising a polynucleotide encoding at least one of estrogen related receptor (ERR) alpha (ERRα) and estrogen related receptor gamma (ERRγ) and expressing at least one of ERRα or ERRγ in the cells 3-5 days following step (a), wherein the expression of the at least one of ERRα and ERRγ in the cells results in the upregulation of an ERRα or ERRγ cofactor selected from Peroxisome proliferator-activated receptor Gamma Coactivator 1 alpha (PGC-1α) or Peroxisome proliferator-activated receptor Gamma Coactivator 1 beta (PGC-1β) in the cells, thereby generating a reprogrammed mammalian induced pluripotent stem cell; and
(c) culturing said reprogrammed mammalian induced pluripotent stem cell.

5. The method of claim 4 , further comprising isolating the mammalian induced pluripotent stem cell from the culture.

6. The method of claim 1 , wherein the one or more viral vectors in step (a) and step (b) is a lentivirus vector.

7. The method of claim 2 , wherein the one or more viral vectors in step (a) and step (b) is a lentivirus vector.

8. The method of claim 3 , wherein the one or more viral vectors in step (a) and step (b) is a lentivirus vector.

9. The method of claim 4 , wherein the one or more viral vectors in step (a) and step (b) is a lentivirus vector.

10. The method of claim 3 , further comprising isolating the reprogrammed human induced pluripotent stem cell from the culture.

11. The method of claim 8 , wherein the mouse embryonic fibroblast progenitor cell expressing Oct4, Sox2, Klf4 and cMyc reprogramming factors in step (a) has an undetectable level of at least one of stem cell antigen 1 (Sca1) and CD34 protein.

12. The method of claim 2 , wherein the human fibroblast progenitor cells or human adipose stem cell progenitor cells expressing Oct4, Sox2, Klf4 and cMyc reprogramming factors in step (a) have an undetectable level of at least one of stem cell antigen 1 (Sca1) and CD34 protein.

13. The method of claim 3 , wherein the human fibroblast progenitor cells or adipose stem cell progenitor cells expressing Oct4, Sox2, Klf4 and cMyc reprogramming factors in step (a) have an undetectable level of at least one of stem cell antigen 1 (Sca1) and CD34 protein.

Assignees

• Salk Inst For Biological Studi

Inventors

• Evans Ronald
• Downes Michael
• Kida Yasuyuki
• Kawamura Teruhisa
• Wei Zong
• Yu Ruth T
• Atkins Annette R

Classifications

• C12N2510/00

  Genetically modified cells · CPC title

• C12N5/0696 Primary

  Artificially induced pluripotent stem cells, e.g. iPS · CPC title

• C12N2506/1307

  from adult fibroblasts · CPC title

• C12N2501/39

  Steroid hormones · CPC title

• C12N2506/02

  from embryonic cells · CPC title